, increased by THB 31 million or 2.9%. Cash Flows As of 31 March 2018, cash and cash equivalents was THB 732 million, decreasing by THB 289 million from THB 1,021 million as of 31 December 2017. Source of Funds
administrative expenses as a percentage of revenues represented 38% in the first quarter of 2018, decreasing from last year. - Bad debt and Doubtful accounts In the first quarter of 2018, the Company posted bad
, the net profit was Baht 43.31 million, decreased by 3.41 million or decreasing by 7.3 percents in which performance for the company and its subsidiaries in the current three-month period compared to the
total borrowings, decreasing from 69% of fiscal year 2017. To manage risk that might occur from the fluctuation in currency and interest rate of long-term a debenture in foreign currencies, the Company
THB 314.21 million, decreasing 53.38% from the end of last year. Total liabilities comprise mostly short-term loans from financial institutions, trade payables and other payables and long-term loans
previous year. This came from decreasing in services revenue whereas sales revenues from medical devices still increased. Revenues from sales and services of EFORL and its subsidiaries in Q3/2018 increased
newl 0 per share t offering) with t 0.53 per sha 18 to 24 Dece are remaining onate to their g shareholde e newly issue ued ordinary issued ordina decreasing here is any s ng shareholdi (including the
-bearing debt to equity ratio of 2.41x, decreasing from 2.49x as of 31 December 2019. This was caused by decreased interest-bearing liabilities due to repayment of long- term loans and leasing loans as well
decreasing in ordinary shares of non- controlling interests of Baht 0.81 million. 2. The separate financial statements 2.1 Report and analysis of Business Operations Revenue Revenue from operations Revenue
million and loss on loan to subsidiary of Baht 350 million. The loss for the period of YE 2019 is Baht 358 million decreasing by 42% from last year (YE2018: 621 million). However the Company is in the